IMUNON Signs CRADA With National Cancer Institute for IMNN-001

The NCI's Cancer Therapy Evaluation Program will sponsor and fund new trials of IMUNON's DNA-based IL-12 immunotherapy in additional solid tumors.

Share
Imunon's IMNN-001 is a DNA-based IL-12 immunotherapy delivered by nanoparticle.